For those prescribed GLP-1 medications specifically for weight management (Wegovy or Saxenda), treatment continuation will be assessed according to NICE criteria, which typically require a minimum percentage weight loss within a specified timeframe
The mechanisms by which TMAO raises CV risk and accelerates atherosclerosis are not well understood, but studies have shown that TMAO arising from both choline and L-carnitine supplementation in mice may inhibit reverse cholesterol transport 35 and enhance foam cell formation in both arterial and peritoneal cavity 47
Further, access issues, market shortages, insurance coverage, and the ethics of off-label use were found to be discussed
108 Overall, these studies suggest that although weight loss from dietary restriction can compromise skeletal health, incorporating exerciseparticularly endurance trainingcan preserve BMD and hormonal factors, and reduce bone resorption, thereby offering partial protection to the skeleton during obesity treatment
Drug makers remain busy investing in new drug delivery technologies and oral peptide formulations, even as clinical interest rises